News

Court awards claimant $13.5m in rofecoxib lawsuit

BMJ 2006; 332 doi: 10.1136/bmj.332.7547.927-a (Published 20 April 2006)
Cite this as: BMJ 2006;332:927.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Janice Hopkins Tanne
  1. New York

    A jury in New Jersey has awarded $4.5m (£2.6m; €3.7m) in compensatory damages to a 77 year old man who claimed that rofecoxib (Vioxx) had caused his heart attack. The jury decided that Merck, the maker of the cyclo-oxygenase-2 inhibitor, had deceived the US Food and Drug Administration about the safety of the drug and awarded the man an additional $9m in punitive damages.

    Merck said it had given the FDA all the necessary information about rofecoxib and would appeal the ruling.

    The jury decided that the heart attack …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular